Back to Authors

Balasubramanian, Karthick

Mayo Clinic

Christian Medical College, Vellore

Citations 1

Comparative Outcomes of Intra-Aortic Balloon Pump Versus Percutaneous Left Ventricular Assist Device in High-Risk Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Sivasubramanian, Dhiran , Senthilkumar, Virushnee, Palanisamy, Nithish Nanda, Bilgaiyan, Rashi, Aravind, Smrti , Kumar, Sri Drishaal, Balasubramanian, Aishwarya , Sanil, Sathwik , Balasubramanian, Karthick, Kamaladasan, Dharssini, Pilathodan, Hashwin, Shankar, Kiruba, Nanda Palanisamy, Nithish , Kumar, Sri Drishaal, Balasubramanian, Aishwarya

Journal of Clinical Medicine | August 5, 2025 | Volume: 14 | Issue: 15 | Pages: 5430

10.3390/jcm14155430 Get It

Background/Objectives: High-risk percutaneous coronary interventions (HR-PCIs) often require mechanical circulatory support (MCS) to maintain hemodynamic stability. Intra-aortic balloon pump (IABP) and percutaneous left ventricular assist device (PLVAD) are two commonly used MCS devices that differ in their mechanisms. We aimed to evaluate and compare the clinical outcomes associated with IABP and PLVAD use in HR-PCIs without cardiogenic shock. Methods: We conducted a search of PubMed, Scopus, Cochrane, Mendeley, Web of Science, and Embase to identify relevant randomized controlled trials and cohort studies, and we included 13 studies for the systematic review and meta-analysis. The primary goal was to define the difference in early mortality (in-hospital and 30-day mortality), major bleeding, and major adverse cardiovascular event (MACE) components (cardiogenic shock, acute kidney injury (AKI), and stroke/TIA) in IABP and PLVAD. We used a random-effects model with the Mantel–Haenszel statistical method to estimate odds ratios (ORs) and 95% confidence intervals. Results: Among 1 trial and 12 cohort studies (35,554 patients; 30,351 IABP and 5203 PLVAD), HR-PCI with IABP was associated with a higher risk of early mortality (OR = 1.53, 95% CI [1.21, 1.94]) and cardiogenic shock (OR = 2.56, 95% CI [1.98, 3.33]) when compared to PLVAD. No significant differences were found in the rates of arrhythmia, major bleeding, AKI, stroke/TIA, or hospital length of stay. Conclusions: In high-risk PCIs, PLVAD use is associated with lower early mortality and cardiogenic shock risk compared to IABP, with no significant differences in other major outcomes.